TRON has been shortlisted for Cancer Research UK’s Grand Challenge Award as part of team BLUEPRINT
TRON is part of a multi-disciplinary team of scientists that has been shortlisted to the final stages of Cancer Research UK’s Grand Challenge*. The team is led by Dr. Lindy Durrant from the University of Nottingham and includes our close cooperation partner BioNTech and its associate Genentech. Cancer Research UK’s Grand Challenge is an ambitious series of £20m global grants tackling some of the toughest questions in cancer research.
Team BLUEPRINT’s goal is to probe the full potential of the tumour vaccine concept by building blueprints for an effective therapy for patients with most types of cancer. Blueprint envisions a future in which every cancer patient will be offered a vaccine that is tailored to the genetic and antigenic profile of their tumour as a standard-of-care treatment.
The team has received seed-funding to draft their full research proposal, and winning teams will be announced in autumn 2018.
This is the second round of Cancer Research UK’s Grand Challenge award and last year four teams were awarded up to £20 million each*.
* See website for more information: http://www.cancerresearchuk.org/funding-for-researchers/how-we-deliver-research/grand-challenge-award